Disrupt HER2 signaling with a dual blockade
PERJETA® (pertuzumab) works with Herceptin® (trastuzumab) and docetaxel to inhibit HER2 dimerization for a more comprehensive blockade
PERJETA and HER2+ breast cancer
See how PERJETA targets HER2 receptors in HER2+ breast cancer.
Financial assistance for patients
Genentech has multiple programs that may help your patients receive
Request more information
Genentech Clinical Oncology Specialists are available to answer your
questions about PERJETA.